Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ctacutestrokebrainonset
  Phrases that lowered it: drugclinicaleffectand safetyblood pressure
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Drug's FAERS reports with a death: 37.1% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 98.6% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Blinding: double (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 704 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Norwegian Tenecteplase Stroke Trial 2 NCT03854500 · started 2019 · scored riskier than 87% of active trials terminated
• Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis NCT02814409 · started 2016 · scored riskier than 84% of active trials completed
• CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II NCT04516993 · started 2021 · scored riskier than 19% of active trials completed
• Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST) NCT01472926 · started 2011 · scored riskier than 94% of active trials completed
• Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance NCT04071613 · started 2019 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.